 |
Research Article
Outcome of patients with glioblastoma treated with Stupp protocol, 10-year review: A single center retrospective study
1 Department of Medical Oncology, Mid-West Cancer Centre, University Hospital Limerick, Limerick, Ireland
2 Mid-West Radiation Oncology Centre, University Hospital Limerick, Limerick, Ireland
Address correspondence to:
Ruba A Hamed
Department of Medical Oncology, Mid-West Cancer Centre, University Hospital Limerick, Limerick,
Ireland
Message to Corresponding Author
Article ID: 100011C01RH2022
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Hamed RA, Mahgoub T, Lowry L, Elbassiouni M, Korpanty G. Outcome of patients with glioblastoma treated with Stupp protocol, 10-year review: A single center retrospective study. Edorium J Cancer 2022;7:100011C01RH2022.ABSTRACT
Aims: Glioblastoma (GBM) is the most aggressive malignant brain tumor. In 2005, Stupp et al. demonstrated an increase in median overall survival (OS) to 14.6 months using radical radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). We aim to review the outcome and OS of patients treated with the Stupp regimen in our center.
Methods: Retrospective analysis of 64 patients diagnosed with GBM between 2008 and 2018 and treated under Stupp protocol. Data collected from electronic records and survival analysis was completed using the Kaplan–Meier method.
Results: The median age was 59 years; 70% (45) were male. 76.6% (49) underwent debulking surgery, and 23.4% had biopsy only. 78% (50) completed concurrent RT and TMZ. 65.6% (42) proceeded to have adjuvant TMZ with a median of 5.5 cycles. The median OS for the whole cohort was 13.2 months (95% CI 10–15.4). Median OS for patients who had debulking surgery was 14.5 months, versus 11.1 months for patients with biopsy (p=0.62). Patients who received adjuvant TMZ after concurrent RT-TMZ had OS of 15.6 months, compared to 9.6 months for patients who did not receive adjuvant TMZ (p=0.004).
Conclusion: The median OS survival of our cohort was slightly inferior to what was observed in the Stupp trial.
Keywords: Glioblastoma, Outcome, STUPP, Temozolomide
SUPPORTING INFORMATION
Author Contributions
Ruba A Hamed - Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Final approval of the version to be published
Thamir Mahgoub - Revising it critically for important intellectual content, Final approval of the version to be published
Laura Lowry - Substantial contributions to conception and design, Interpretation of data, Drafting the article, Final approval of the version to be published
Mazin Elbassiouni - Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Greg Korpanty - Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2022 Ruba A Hamed et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
